First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
2016 ◽
Vol 22
(12)
◽
pp. 2874-2884
◽
2012 ◽
Vol 18
(15)
◽
pp. 4173-4182
◽
2011 ◽
Vol 18
(4)
◽
pp. 1092-1100
◽
2011 ◽
Vol 17
(6)
◽
pp. 1582-1590
◽